At CD BioGlyco, we meticulously attend to every aspect of Glycosylation Inhibitor Development, aiming for excellence in each step, as demonstrated by our extensive track record of success over the years. We provide numerous GAG inhibitor development services, including but not limited to the following:
HS is a naturally occurring complex polysaccharide known for its anticoagulant properties within the human body. Leveraging years of in-depth research and expertise in HS, CD BioGlyco offers professional and comprehensive HS inhibitor development services.
Heparin is a polysaccharide anticoagulant molecule which primarily synthesized by cells in the liver and lung tissue. In certain pathological conditions, excessive production of heparin by the body can result in bleeding or impaired clotting. Consequently, the development of heparin inhibitors has become an urgent priority.
Through the development of CS inhibitors, it is feasible to specifically intervene in its function in disease progression, thereby aiding in disease management. CD BioGlyco provides inhibitor development services that target CS biosynthesis processes.
CD BioGlyco has developed a wide range of comprehensive solutions to facilitate the development of DS inhibitors. Our primary focus is to assist academic laboratories and industries in exploring the biological and pharmaceutical effects of DS inhibitors.
CD BioGlyco offers specialized hyaluronan inhibitor development services, encompassing comprehensive support from drug screening to preclinical research. Collaborating with us ensures access to highly competitive hyaluronan inhibitor development services, expediting advancements in your research.
Intervening in the synthesis or degradation of KS through the use of KS inhibitors presents a valuable approach for exploring new targets and strategies. At CD BioGlyco, we provide top-notch KS inhibitor development services that consistently meet and exceed the expectations of our clients in terms of quality and effectiveness.
Technology: Immunofluorescence staining, Bioinformatics analysis technology
Journal:Angewandte Chemie International Edition
Results: This paper focuses on the use of a visualized chain termination inhibitor, UDP-4-azido-4-deoxyxylose (UDP-4-XylAz), to block GAG biosynthesis in developing zebrafish. Then the authors concluded that UDP-4-XylAz is a potent inhibitor of chain-terminating metabolism that inhibits GAG biosynthesis in zebrafish. The compound has the unique property of being able to visualize the site of its inhibitory action in vivo through a bioorthogonal reaction with fluorescent cyclooctyne. Differences in GAG content in UDP-4-XylAz-treated embryos compared to untreated embryos may contribute to the specific embryonic developmental defects observed.
Fig.1 Xylose initiates diverse GAG structures and can therefore be targeted for metabolic replacement with a visualizable chain-truncating analog. (Beahm, et al., 2014)
CD BioGlyco boasts expert inhibitor development teams and cutting-edge technology, offering clients unmatched GAG inhibitor development services and comprehensive post-sales support for research projects. We are confident in our ability to serve as your indispensable research partner in the field of glycobiology. For further information regarding our services, please feel free to contact us.